This article is a correction to:
Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium
Michaël R. Laurent1*
Jean De Schepper2,3Dominique Trouet4,5
Nathalie Godefroid6Emese Boros7Claudine Heinrichs7Bert Bravenboer8Brigitte Velkeniers8Johan Lammens9Pol Harvengt10Etienne Cavalier11Jean-François Kaux12
Jacques Lombet13Kathleen De Waele3Charlotte Verroken14Koenraad van Hoeck4,5Geert R. Mortier15
Elena Levtchenko16
Johan Vande Walle17- 1Centre for Metabolic Bone Diseases, University Hospitals Leuven, Leuven, Belgium
- 2Division of Pediatric Endocrinology, KidZ Health Castle, University Hospital Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium
- 3Department of Pediatric Endocrinology, University Hospital Ghent, Ghent, Belgium
- 4Department of Pediatric Nephrology, Antwerp University Hospital, Antwerp, Belgium
- 5Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium
- 6Pediatric Nephrology, Cliniques Universitaires St. Luc (UCL), Brussels, Belgium
- 7Paediatric Endocrinology Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles, Brussels, Belgium
- 8Department of Endocrinology, University Hospital Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium
- 9Department of Orthopaedic Surgery and Department of Development and Regeneration, Prometheus LRD Division of Skeletal Tissue Engineering, KU Leuven - University Hospitals Leuven, Leuven, Belgium
- 10XLH Belgium, Belgian XLH patient association, Waterloo, Belgium
- 11Department of Clinical Chemistry, University Hospital Center of Liège, University of Liège, Liège, Belgium
- 12Physical Medicine, Rehabilitation and Sports Traumatology, University and University Hospital of Liège, Liège, Belgium
- 13Division of Nephrology, Department of Pediatrics, University Hospital Center of Liège, Liège, Belgium
- 14Unit for Osteoporosis and Metabolic Bone Diseases, Department of Endocrinology and Metabolism, Ghent University Hospital, Ghent, Belgium
- 15Department of Medical Genetics, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium
- 16Department of Pediatrics/Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium
- 17Department of Pediatric Nephrology, University Hospital Ghent, Ghent, Belgium
A Corrigendum on
Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium
by Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, Bravenboer B, Velkeniers B, Lammens J, Harvengt P, Cavalier E, Kaux J-F, Lombet J, De Waele K, Verroken C, van Hoeck K, Mortier GR, Levtchenko E and Vande Walle J (2021). Front. Endocrinol. 12:641543. doi: 10.3389/fendo.2021.641543
There is an error in the Conflict of Interest statement. The correct statement is “ML has received lecture and consultancy fees from Alexion, Amgen, Kyowa Kirin, Menarini, Sandoz, Takeda, UCB and Will-Pharma. JS has received lecture, consultancy fees, and conference support from Kyowa Kirin, Alexion, Eli-Lily, Ferring, Ipsen, Menarini, Novo Nordisk, Pfizer, Sandoz, and Siemens Healthcare. DT has received conference support from Novo Nordisk. NG, JLa, and KH have received consultancy fees from Kyowa Kirin. EB has received conference support from Novo Nordisk and Pfizer. CH has received conference support from Novo Nordisk and Ferring. EC has received consultancy fees from bioMérieux, Diasorin, Fujirebio, IDS, and Menarini. PH is an employee of GlaxoSmithKline but participates in his own capacity. J-FK has received consultancy fees and conference support from Heel Belgium, Sanofi, and TRB Chemedica. KW has received conference support from Alexion, Ferring, Kyowa Kirin and Novo Nordisk. CV has received conference support from Boehringer Ingelheim. GM has received consultancy fees from Alexion, Biomarin, Kyowa Kirin, and Pfizer. EL has received consultancy fees and travel support from Kyowa Kirin, Chiesi, and Recordati. JV has received conference support and consultancy fees from Alexion, Bellco, Ferring, Medtronic, and Kyowa Kirin.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
There should be a change to Treatment section. A 0.4 mg/kg bodyweight dose is mentioned, whereas the most recently approved dose is a 0.8 mg/kg bodyweight dose. In the subsection “Burosumab” in the fifth paragraph, the first sentence should read as follows: The EMA-approved dose in children is a 2-weekly s.c. injection starting 0.8 mg/kg bodyweight, increased with 0.4 mg/kg dose increments (max. 2.0 mg/kg, cap at 90 mg dose) to achieve fasting plasma phosphate concentrations in the low-normal range for age.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: Burosumab, fibroblast growth factor 23, osteomalacia, rickets, vitamin D, X-linked hypophosphatemia
Citation: Laurent MR, De Schepper J, Trouet D, Godefroid N, Boros E, Heinrichs C, Bravenboer B, Velkeniers B, Lammens J, Harvengt P, Cavalier E, Kaux J-F, Lombet J, De Waele K, Verroken C, van Hoeck K, Mortier GR, Levtchenko E and Vande Walle J (2021) Corrigendum: Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium. Front. Endocrinol. 12:686401. doi: 10.3389/fendo.2021.686401
Received: 26 March 2021; Accepted: 29 March 2021;
Published: 25 May 2021.
Approved by:
Frontiers in Endocrinology Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Laurent, De Schepper, Trouet, Godefroid, Boros, Heinrichs, Bravenboer, Velkeniers, Lammens, Harvengt, Cavalier, Kaux, Lombet, De Waele, Verroken, van Hoeck, Mortier, Levtchenko and Vande Walle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michaël R. Laurent, bWljaGFlbC5sYXVyZW50QHV6bGV1dmVuLmJl